You are here: Industry Insights > Regeneron

News List

Sanofi, Regeneron to cut price of Praluent pharmatimes
July 24, 2018
Selina McKee Sanofi and Regeneron have pledged to make Praluent more accessible to patients as data show that the drug significantly cut the risk of cardiovascular events in high-risk patients.
Atopic dermatitis patients to be denied NHS access to Dupixent pharmatimes
July 19, 2018
The National Institute for Health and Care Excellence has issued draft guidance rejecting Sanofi/Regeneron’s Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis.
Regeneron, Sanofi's drug shows positive effect in lung cancer study biospectrumasia
May 21, 2018
Regeneron's U.S. marketing application seeking approval for cemiplimab, a PD-1 inhibitor, for cutaneous squamous cell carcinoma is currently under FDA review with an action date of October 28.
Regeneron halts high doses of phase 3 osteoarthritis drug fasinumab amid risk-benefit concerns fiercebiotech
May 04, 2018
Regeneron has halted the higher-dose arms of its phase 3 fasinumab trials on the recommendation of a data monitoring committee. The committee made the call after assessing the risk-benefit profile of the osteoarthritis regimens based on data generated to
Regeneron needs revved-up newcomers to backstop vulnerable Eylea—and so far, they're falling short fiercepharma
May 04, 2018
Regeneron's 15% growth in the first quarter came from its aging eye injection Eylea, while its newer drugs came short of expectations. That's not good—particularly with two potential new rivals threatening that blockbuster lead medication.
Regeneron and Alnylam Team up to Tackle NASH Liver Disease biospace
March 23, 2018
Regeneron Pharmaceuticals, Inc. and Alnylam Pharmaceuticals signed a collaborationdeal to identify RNAi therapies for nonalcoholic steatohepatitis (NASH) and other possibly related liver diseases.
Regeneron's Eylea smashes Phase 3 trial goal in diabetic retinopathy pharmafile
March 21, 2018
Regeneron has confirmed that its vascular endothelial growth factor (VEGF) inhibitor injection of Eylea (Aflibercept) reached its primary endpoint in a recent phase III study
Regeneron’s Eylea Shows Promising Data for Diabetic Retinopathy biospace
March 20, 2018
Regeneron Pharmaceuticals, Inc. announced positive topline data from its Phase III PANORAMA clinical trial of Eylea (aflibercept) injection in moderately severe to severe non-proliferative diabetic retinopathy.
Sanofi and Regeneron Slash Cost of New Cholesterol Drug Praluent biospace
March 13, 2018
One of the reasons the new class of cholesterol-lowering medications, PCSK9 inhibitors, have had trouble gaining traction in the marketplace is because of cost
Sanofi and Regeneron Seek FDA Approval of Dupixent as Add-On Asthma Therapy biospace
March 05, 2018
Asthma patients may soon have a new treatment option.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page